Major Depressive Disorder
Conditions
Keywords
Major Depressive Disorder, Intradermal Acupuncture, Magnetic Resonance Imaging
Brief summary
Major depressive disorder (MDD) is a common mental illness that severely affects the health and quality of life of patients. Treatment with acupuncture alone or a combination of appropriate adjuncts has been reported to be significantly effective in reducing the severity of MDD, relieving patients' somatic symptoms and improving sleep. This study will focus on the intradermal acupuncture, which is more convenient, gentler and has longer lasting effects. The aim is to study the efficacy and safety of intradermal acupuncture for MDD, and to preliminarily explore the central nervous mechanisms by which it exerts its therapeutic effects.
Detailed description
A total of 90 patients with MDD who meet the inclusion criteria will be included in the study. Participants will be randomly assigned 1:1:1 to the waiting list group (patients in this group will be treated with selective 5-hydroxytryptamine reuptake inhibitors (SSRIs) only), sham intradermal acupuncture combined with SSRIs (SIA) group and active intradermal acupuncture combined with SSRIs (AIA) group. The study will assess the efficacy and safety of intradermal acupuncture for MDD and examine whether intradermal acupuncture reduces side effects and improves the efficacy of SSRIs for MDD. In addition, the study will use magnetic resonance imaging (MRI) to study the possible central mechanisms by which intradermal acupuncture exerts its antidepressant effects.
Interventions
DRUGSSRIs
SSRIs antidepressants, including fluoxetine, paroxetine, sertraline, citalopram, etc., will be administered at oral doses determined by the psychiatrist. Once daily for 6 weeks.
PROCEDURESIA
This study will select 4 acupoints (all taken bilaterally) commonly used to treat MDD, namely Taichong (LR3), Neiguan (PC6), Sanyinjiao (SP6) and Shenmen (HT7). The SIA will use the same size, colour and material as the AIA with a thin silicone pad in the middle instead of the needle body. SIA will be attached to the acupoints and retained for 72 hours, removed and rested for one day. A total of 10 sessions will be performed over a period of 6 weeks.
PROCEDUREAIA
This study will select 4 acupoints (all taken bilaterally) commonly used to treat MDD, namely Taichong (LR3), Neiguan (PC6), Sanyinjiao (SP6) and Shenmen (HT7). Depending on acupoints' location, a φ0.20\*1.5mm or φ0.20\*1.2mm AIA will be selected. Press the AIA to insert it vertically into the acupoint and retain it in the skin. AIA will be retained for 72 hours with a day's rest after removal. During the period of needle retention, participants will be instructed to press the AIA 3-4 times a day for approximately 1 minute each time, with as much stimulation as the patient can tolerate, at intervals of approximately 4 hours. A total of 10 sessions will be performed over a period of 6 weeks.
Sponsors
Zhejiang Provincial Tongde Hospital
First People's Hospital of Hangzhou
The First Affiliated Hospital of Zhejiang Chinese Medical University
Xiaomei Shao
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
1. Patients diagnosed with MDD according to the International Classification of Disease-10 (ICD-10); 2. Aged between 18 and 60 years (no limitation on gender); 3. No depression-related treatment in the past two weeks, except SSRIs; 4. Patients undergoing MRI and MRS should be right-handed and free of traumatic brain injury, claustrophobia or metal implants; 5. Written informed consent is obtained by the person or guardian.
Exclusion criteria
1. ICD-10 diagnoses: schizophrenia, bipolar disorder, manic episode or other psychotic disorders; alcohol and drug addiction; 2. Significant skin lesions, severe allergic diseases, tumors, and severe or unstable internal diseases involving the cardiovascular, digestive, endocrine, or hematological system; 3. Acute suicidal tendency; 4. Allergy to adhesive tape and fear of intradermal acupuncture; 5. Pregnancy and lactation; 6. Mental retardation and difficult to cooperate with doctors. 7. Participating in other clinical trials.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes in the Hamilton Depression Scale-17 (HAMD-17) Scores | Baseline, 3 weeks after treatment, 6 weeks after treatment, at 4-week follow-up. | The HAMD scale is the most commonly used in the clinical assessment of depression, including 17 items. The higher the score, the more severe the depression. 0-7 means no depressive symptoms, 8-17 means mild depression, 18-24 was divided into moderate depression, and 25-52 was divided into severe depression. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes in the Pittsburgh Sleep Quality Index (PSQI) Scores | Baseline, 3 weeks after treatment, 6 weeks after treatment, at 4-week follow-up | The PSQI is used to assess the sleep quality of the participant in the last 1 month and consisted of 19 self-rated and 5 other rated items. The higher the score, the worse the sleep quality. Sleep quality is divided into 4 levels according to the total score. |
| Changes in the Self-Rating Depression Scale (SDS) Scores | Baseline, 3 weeks after treatment, 6 weeks after treatment, at 4-week follow-up | The standard score is the total of all scores multiplied by 1.25 to the nearest whole number on this scale, which has 20 questions. A standard score below 50 is normal; 50-60 is mild depression; 61-70 is moderate depression; 70 or more is severe depression. |
| Changes in the Treatment Emergent Symptom Scale (TESS) Scores | Baseline, 6 weeks after treatment | The TESS is often used to assess the side effects of drugs. It contains 35 symptom items and 2 total assessment items, including behavioural toxicity, laboratory tests, autonomic nervous system, nervous and cardiovascular system, etc. Each of these symptoms is graded into 5 levels of severity (0-4), with the higher the score the more severe the side effects. |
| Adverse Events | Up to 10 weeks | Adverse events such as bleeding, haematoma, or unbearable pain caused by the needle, as well as drug-induced nausea, vomiting or dizziness, will all be recorded. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Blood samples biobank establishment | Baseline, 6 weeks after treatment | Blood samples will be collected to test the function of the hypothalamic-pituitary-adrenal axis, including the level of adrenocorticotropic hormone (ACTH) and cortisol (Cor). |
| Magnetic resonance spectroscopy (MRS ) data acquisition | Baseline, 6 weeks after treatment | MRS will be taken by the 3.0 T magnetic resonance scanner to detect the neurometabolic change in patients' brain regions, particularly the hypothalamus, before and after the intervention. |
| Magnetic resonance imaging (MRI) data acquisition | Baseline, 6 weeks after treatment | Brain MRI will be taken by the 3.0 T magnetic resonance scanner to analyse the functional connectivity of the patient's brain regions, particularly the hypothalamus, before and after the intervention. |
Countries
China
Contacts
Primary ContactXiaomei Shao, Ph.D
Backup ContactXiaoting Wu
Outcome results
None listed